Clinical trial

Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)

NCT04627402

Study summary

ClinicalTrials.gov

Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: NA

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Conbercept and TA Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Conbercept Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2020-11-12

PhaseNA

Conditions

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Macular Edemaverified · MONDO: macular retinal edema

Interventions

Conbercept and TADRUG

ConberceptDRUG

Sponsors & collaborators

Zhongshan Ophthalmic Center, Sun Yat-sen Universitylead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04627402 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.